BeiGene's (HKG:6160, SHA:688235) loss narrowed to $371.6 million in the first half from $729.6 million in the year-ago period, according to a Tuesday filing with the Hong Kong Stock Exchange.
Loss per share at the drug company halved to $0.27 from $0.54 a year earlier. Analysts polled by Visible Alpha expected a loss per share of $0.01.
Revenue grew to $1.68 billion from $1.04 billion the previous year. The Visible Alpha consensus forecast was $928.5 million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。